CHF Solutions, Inc. Announces 49.5 Percent Increase in Revenue for Fourth Quarter 2020 and Provides Company Update
CHF Solutions, Inc. (Nasdaq: CHFS) reported a strong fourth quarter for 2020 with a revenue increase of 49.5% to $2 million compared to the previous year. Gross margin rose to 56.1%, up from 50.8% in 2019, driven by higher utilization of the Aquadex System during the COVID-19 pandemic.
Operating expenses increased by 5.7% to $5.4 million, while net loss improved to $3.1 million from $4.4 million a year prior. The company ended the year with $14.4 million in cash and no debt.
- Revenue increased by 49.5% to $2 million in Q4 2020.
- Gross margin improved to 56.1%, up from 50.8% in Q4 2019.
- Sequential revenue growth for five consecutive quarters.
- Addition of five new pediatric accounts to boost utilization.
- Successful CPT code application submitted for outpatient access.
- Net loss for Q4 2020 was $3.1 million, despite improvement from previous year.
- Operating expenses rose by 5.7% to $5.4 million.
EDEN PRAIRIE, Minn., March 02, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter ended December 31, 2020.
Recent Highlights
- Revenue for the fourth quarter of 2020 was
$2 million , an increase of49.5% compared to the prior year period - Gross margin was
56.1% for the fourth quarter 2020, up from50.8% in the corresponding period in 2019 and up from46.1% in the third quarter of 2020 - Critical Care revenue benefited in the quarter from increased utilization from hospitals treating COVID-19 patients with the Aquadex System.
- Continued to see strong momentum in pediatric accounts, adding 5 new locations including Children’s Hospitals in Philadelphia, Houston, and the San Francisco Bay Area
- Presented a 355 consecutive patient retrospective study at the Annual Scientific Meeting of Heart Failure Society of America, which showed substantial mean fluid removal with no negative changes in renal function and reduced rehospitalization rates in patients treated with Aquadex therapy
- Successfully submitted CPT code application for ultrafiltration using Aquadex SmartFlow, which will provide access to heart failure patients in the outpatient setting
- Cash and cash equivalents totaled
$14.4 million with no debt as of December 31, 2020
“CHF Solutions built on its momentum over the last few quarters, having delivered solid fourth quarter results, most notably within critical care and pediatric accounts,” said Nestor Jaramillo, CEO of CHF Solutions. “We anticipate that when healthcare systems return to some level of the new normal, we are strongly positioned to see accelerating sales growth as a leading and primary provider of ultrafiltration therapy to cardiologists, nephrologists, hospitalists, intensivists, cardiac surgeons, and pediatricians who treat fluid overload.”
Fourth Quarter 2020 Financial Results
Revenue for the fourth quarter was
Gross margin was
Operating expenses for the fourth quarter of 2020 were
The Company recognized a gain of
The Company used
Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit http://ir.chf-solutions.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 5495878. An audio archive of the webcast will be available following the call at http://ir.chf-solutions.com/events.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the value that the company brings to its customers. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Financials
CHF SOLUTIONS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||||
| Net sales | $ | 2,044 | $ | 1,367 | $ | 7,441 | $ | 5,511 | ||||||||||
| Costs and expenses: | ||||||||||||||||||
| Cost of goods sold | 897 | 673 | 3,384 | 2,660 | ||||||||||||||
| Selling, general and administrative | 4,384 | 4,187 | 17,417 | 16,285 | ||||||||||||||
| Research and development | 1,047 | 953 | 3,668 | 4,672 | ||||||||||||||
| Total costs and expenses | 6,328 | 5,813 | 24,469 | 23,617 | ||||||||||||||
| Loss from operations | (4,284 | ) | (4,446 | ) | (17,028 | ) | (18,106 | ) | ||||||||||
| Realized foreign currency translation gain from dissolution of subsidiary | 1,202 | - | 1,202 | - | ||||||||||||||
| Other income (expense), net | (2 | ) | 1 | (1 | ) | - | ||||||||||||
| Loss before income taxes | (3,084 | ) | (4,445 | ) | (15,827 | ) | (18,106 | ) | ||||||||||
| Income tax expense | (2 | ) | (3 | ) | (9 | ) | (8 | ) | ||||||||||
| Net loss | $ | (3,086 | ) | $ | (4,448 | ) | $ | (15,836 | ) | $ | (18,114 | ) | ||||||
| Basic and diluted loss per share | $ | (1.13 | ) | $ | (33.46 | ) | $ | (10.67 | ) | $ | (278.90 | ) | ||||||
| Weighted average shares outstanding – basic and diluted | 2,736 | 133 | 1,649 | 81 | ||||||||||||||
| Other comprehensive loss: | ||||||||||||||||||
| Realized foreign currency translation gain from dissolution of subsidiary | $ | (1,202 | ) | $ | - | $ | (1,202 | ) | $ | - | ||||||||
| Unrealized foreign currency translation adjustments | $ | (12 | ) | $ | (5 | ) | $ | (19 | ) | $ | (9 | ) | ||||||
| Total comprehensive loss | $ | (4,300 | ) | $ | (4,453 | ) | $ | (17,057 | ) | $ | (18,123 | ) | ||||||
CHF SOLUTIONS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, 2020 | December 31, 2019 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 14,437 | $ | 1,279 | ||||
| Accounts receivable | 905 | 799 | ||||||
| Inventories | 2,957 | 1,797 | ||||||
| Other current assets | 237 | 161 | ||||||
| Total current assets | 18,536 | 4,036 | ||||||
| Property, plant and equipment, net | 1,200 | 991 | ||||||
| Operating lease right-of-use asset, net | 255 | 442 | ||||||
| Other assets | 21 | 133 | ||||||
| TOTAL ASSETS | $ | 20,012 | $ | 5,602 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,097 | $ | 1,488 | ||||
| Accrued compensation | 2,192 | 1,592 | ||||||
| Current portion of operating lease liability | 206 | 186 | ||||||
| Current portion of finance lease liability | 24 | - | ||||||
| Other current liabilities | 66 | 85 | ||||||
| Total current liabilities | 3,585 | 3,351 | ||||||
| Operating lease liability | 55 | 261 | ||||||
| Finance lease liability | 54 | - | ||||||
| Total liabilities | 3,694 | 3,612 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Series A junior participating preferred stock as of December 31, 2020 and December 31, 2019, par value | — | — | ||||||
| Series F convertible preferred stock as of December 31, 2020 and December 31, 2019, par value | — | — | ||||||
| Preferred stock as of December 31, 2020 and December 31, 2019, par value | — | — | ||||||
| Common stock as of December 31, 2020 and December 31, 2019, par value | — | — | ||||||
| Additional paid-in capital | 249,663 | 218,278 | ||||||
| Accumulated other comprehensive income: | ||||||||
| Foreign currency translation adjustment | (7 | ) | 1,214 | |||||
| Accumulated deficit | (233,338 | ) | (217,502 | ) | ||||
| Total stockholders’ equity | 16,318 | 1,990 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 20,012 | $ | 5,602 | ||||
CHF SOLUTIONS, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In thousands)
| For the years ended December 31, | |||||||||
| 2020 | 2019 | ||||||||
| Operating Activities | |||||||||
| Net loss | $ | (15,836 | ) | $ | (18,114 | ) | |||
| Adjustments to reconcile net loss to cash flows from operating activities: | |||||||||
| Depreciation and amortization | 376 | 239 | |||||||
| Stock-based compensation expense | 1,349 | 1,512 | |||||||
| Loss on disposal of property and equipment | 40 | — | |||||||
| Realized foreign currency translation gain from dissolution of subsidiary | 1,202 | — | |||||||
| Changes in operating assets and liabilities: | |||||||||
| Accounts receivable | (106 | ) | (13 | ) | |||||
| Inventories | (1,420 | ) | (343 | ) | |||||
| Other current assets | (76 | ) | 42 | ||||||
| Other assets and liabilities | 112 | 18 | |||||||
| Accounts payable and accrued compensation | 191 | 292 | |||||||
| Net cash used in operations | (16,572 | ) | (16,367 | ) | |||||
| Investing activities: | |||||||||
| Purchase of property and equipment | (298 | ) | (490 | ) | |||||
| Proceeds from the sale of property and equipment | 31 | — | |||||||
| Net cash used in investing activities | (267 | ) | (490 | ) | |||||
| Financing activities: | |||||||||
| Proceeds from public stock offerings, net | 25,921 | 12,665 | |||||||
| Proceeds from warrant exercises | 4,115 | — | |||||||
| Payments on finance lease liability | (20 | ) | — | ||||||
| Net cash provided by financing activities | 30,016 | 12,665 | |||||||
| Effect of exchange rate changes on cash | (19 | ) | (9 | ) | |||||
| Net increase (decrease) in cash and cash equivalents | 13,158 | (4,201 | ) | ||||||
| Cash and cash equivalents—beginning of year | 1,279 | 5,480 | |||||||
| Cash and cash equivalents—end of year | $ | 14,437 | $ | 1,279 | |||||
| Supplemental schedule of non-cash activities | |||||||||
| Financing fees incurred for subsequent equity financing included in other assets and accounts payable | $ | — | $ | 111 | |||||
| Inventory transferred to property, plant and equipment | $ | 260 | $ | 204 | |||||
| Equipment acquired through finance lease liability | $ | 98 | $ | — | |||||
| Supplemental cash flow information | |||||||||
| Cash paid for income taxes | $ | 10 | $ | 4 | |||||
FAQ
What was CHF Solutions' revenue for Q4 2020?
How did CHF Solutions' gross margin change in Q4 2020?
What was the net loss reported by CHF Solutions in Q4 2020?
How much cash did CHF Solutions have at the end of 2020?
What factors contributed to CHF Solutions' revenue growth in Q4 2020?
